154.33

0.62% -0.96

After Hours: 154.33

Quest Diagnostics Inc (DGX)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split Dividend History

Quest Diagnostics Inc stock is traded at $154.33, with a volume of 543.64K. It is down -0.62% in the last 24 hours and up +2.35% over the past month. Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the us. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.

Previous Close:

$155.29

Open:

$155.37

24h Volume:

543.64K

Relative Volume:

0.76

Market Cap:

$17.23B

Revenue:

$9.35B

Net Income/Loss:

$840.00M

P/E Ratio:

23.17

EPS:

6.66

Net Cash Flow:

$875.00M

1W Performance:

-1.02%

1M Performance:

+2.35%

6M Performance:

+12.34%

1Y Performance:

+15.25%

1-Day Range:

$154.00

$156.24

1-Week Range:

$153.55

$157.44

52-Week Range:

$123.04

$160.95

Quest Diagnostics Inc Stock (DGX) Company Profile

Name

Quest Diagnostics Inc

Sector

Healthcare (1180)

Industry

Diagnostics & Research (57)

Phone

(973) 520-2700

Address

500 PLAZA DRIVE, SECAUCUS

Employee

48,000

Twitter

@QuestDX

Next Earnings Date

2024-10-22

Latest SEC Filings

DGX's Discussions on Twitter

Quest Diagnostics Inc Stock (DGX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-28-24	Resumed	Evercore ISI	In-line
Jul-10-24	Upgrade	Citigroup	Neutral → Buy
Feb-26-24	Initiated	Leerink Partners	Market Perform
Feb-07-24	Upgrade	Jefferies	Hold → Buy
Jan-03-24	Initiated	Barclays	Equal Weight
Dec-12-23	Upgrade	BofA Securities	Neutral → Buy
Jun-29-23	Initiated	Piper Sandler	Neutral
May-02-23	Downgrade	BofA Securities	Buy → Neutral
Apr-03-23	Upgrade	Citigroup	Sell → Neutral
Jan-23-23	Initiated	Evercore ISI	In-line
Nov-17-22	Downgrade	Citigroup	Neutral → Sell
Aug-22-22	Resumed	Morgan Stanley	Equal-Weight
Apr-04-22	Downgrade	Citigroup	Buy → Neutral
Feb-23-22	Downgrade	UBS	Buy → Neutral
Feb-02-22	Downgrade	Jefferies	Buy → Hold
Jan-28-22	Downgrade	Deutsche Bank	Buy → Hold
May-04-21	Upgrade	UBS	Neutral → Buy
Mar-12-21	Downgrade	Robert W. Baird	Outperform → Neutral
Oct-21-20	Upgrade	Argus	Hold → Buy
Jul-29-20	Upgrade	KeyBanc Capital Markets	Sector Weight → Overweight
Jul-14-20	Upgrade	BofA Securities	Neutral → Buy
Jun-09-20	Upgrade	Wells Fargo	Underweight → Equal Weight
Jun-02-20	Upgrade	Deutsche Bank	Hold → Buy
Apr-28-20	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Apr-27-20	Upgrade	Citigroup	Neutral → Buy
Apr-27-20	Upgrade	Wolfe Research	Underperform → Peer Perform
Mar-27-20	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Jan-08-20	Initiated	Wells Fargo	Underweight
Jan-07-20	Downgrade	Barclays	Overweight → Equal Weight
Dec-19-19	Upgrade	BofA/Merrill	Underperform → Neutral
Jul-15-19	Downgrade	Goldman	Neutral → Sell
Apr-02-19	Upgrade	Jefferies	Hold → Buy
Mar-18-19	Resumed	Credit Suisse	Neutral
Jan-31-19	Downgrade	Argus	Buy → Hold
Jan-17-19	Initiated	UBS	Neutral
Jan-03-19	Downgrade	BofA/Merrill	Neutral → Underperform
Dec-03-18	Downgrade	BofA/Merrill	Buy → Neutral
Nov-30-18	Downgrade	Goldman	Buy → Neutral

View All

Quest Diagnostics Inc Stock (DGX) Latest News

Nov 03, 2024

New York State Teachers Retirement System Trims Position in Quest Diagnostics Incorporated (NYSE:DGX) - MarketBeat

Nov 03, 2024

Nov 02, 2024

DGX (Quest Diagnostics) PE Ratio : 20.87 (As of Nov. 02, 2024) - GuruFocus.com

Nov 02, 2024

Nov 01, 2024

Quest Diagnostics Inc. stock rises Friday, still underperforms market - MarketWatch

Nov 01, 2024

Quest Diagnostics Incorporated (NYSE:DGX) Shares Sold by State of Alaska Department of Revenue - MarketBeat

Nov 01, 2024

Oct 31, 2024

Quest Diagnostics Incorporated (NYSE:DGX) Holdings Lowered by Assenagon Asset Management S.A. - MarketBeat

Oct 31, 2024

Quest Diagnostics (NYSE:DGX) Upgraded at StockNews.com - MarketBeat

Oct 31, 2024

Oct 30, 2024

Quest Diagnostics' SVP sells shares worth $278,525 By Investing.com - Investing.com Canada

Oct 30, 2024

Quest Diagnostics' SVP sells shares worth $278,525 - Investing.com India

Oct 30, 2024

abrdn plc Has $71.50 Million Stock Position in Quest Diagnostics Incorporated (NYSE:DGX) - MarketBeat

Oct 30, 2024

Oct 29, 2024

Quest Diagnostics Inc. stock rises Tuesday, still underperforms market - MarketWatch

Oct 29, 2024

Oct 28, 2024

Quest Diagnostics (NYSE:DGX) PT Raised to $165.00 - MarketBeat

Oct 28, 2024

Oct 27, 2024

DekaBank Deutsche Girozentrale Has $115.62 Million Holdings in Quest Diagnostics Incorporated (NYSE:DGX) - MarketBeat

Oct 27, 2024

Oct 25, 2024

Director Gregg Vicky B increased direct ownership by 0.42% to 18,045 units (SEC Form 4) - Quantisnow

Oct 25, 2024

SVP & Chief Commercial Officer Delaney Mark E increased direct ownership by 0.08% to 5,023 units (SEC Form 4) - Quantisnow

Oct 25, 2024

Quest Diagnostics Incorporated (NYSE:DGX) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year - Yahoo Finance

Oct 25, 2024

FY2025 EPS Forecast for Quest Diagnostics Reduced by Analyst - MarketBeat

Oct 25, 2024

Quest Diagnostics Incorporated (DGX) Soars to 52-Week High, Time to Cash Out? - Yahoo Finance

Oct 25, 2024

Raymond James & Associates Purchases 14,899 Shares of Quest Diagnostics Incorporated (NYSE:DGX) - MarketBeat

Oct 25, 2024

Oct 24, 2024

Quest Diagnostics Inc. stock outperforms competitors on strong trading day - MarketWatch

Oct 24, 2024

Mizuho Boosts Quest Diagnostics (NYSE:DGX) Price Target to $174.00 - MarketBeat

Oct 24, 2024

Quest Diagnostics: Organic Growth Leads To Q3 Earnings Beat (NYSE:DGX) - Seeking Alpha

Oct 24, 2024

Quest Diagnostics (NYSE:DGX) Stock Rating Upgraded by Baird R W - MarketBeat

Oct 24, 2024

Zacks Industry Outlook Highlights Quest Diagnostics, Encompass Health, Amedisys and Addus HomeCare - Yahoo Finance

Oct 24, 2024

Quest Diagnostics to launch avian flu testing this month By Investing.com - Investing.com Canada

Oct 24, 2024

Quest Diagnostics Inc. stock outperforms competitors despite losses on the day - MarketWatch

Oct 23, 2024

My Quest Story – Martha Baer - StockTitan

Oct 23, 2024

Quest upgraded to outperform by Baird, sector momentum cited - MSN

Oct 23, 2024

Quest Diagnostics (NYSE:DGX) Sets New 12-Month High After Strong Earnings - MarketBeat

Oct 23, 2024

UBS Group Boosts Quest Diagnostics (NYSE:DGX) Price Target to $166.00 - MarketBeat

Oct 23, 2024

Quest Diagnostics stock hits 52-week high of $159.46 By Investing.com - Investing.com Canada

Oct 23, 2024

Quest Diagnostics (NYSE:DGX) Releases Earnings Results, Beats Expectations By $0.04 EPS - MarketBeat

Oct 23, 2024

Quest Diagnostics set to launch a rapid lab test to detect avian influenza A H5 virus - Seeking Alpha

Oct 23, 2024

Quest Diagnostics Incorporated (NYSE:DGX) Q3 2024 Earnings Call Transcript - Insider Monkey

Oct 23, 2024

US lab operator Quest Diagnostics to launch bird flu test at end of October - Reuters.com

Oct 23, 2024

Quest Diagnostics (NYSE:DGX) Rating Increased to Outperform at Robert W. Baird - MarketBeat

Oct 23, 2024

Quest Diagnostics Awarded CDC Contracts for H5 Avian Influenza and Oropouche Virus Test Development - PR Newswire

Oct 23, 2024

Quest Diagnostics: Q3 Earnings Snapshot - The Advocate

Oct 23, 2024

Why Investors Shouldn't Be Surprised By Quest Diagnostics Incorporated's (NYSE:DGX) P/E - Simply Wall St

Oct 23, 2024